Adial Pharmaceuticals Acquires Azora Therapeutics in Deal Worth Up to $64 Million

Adial Pharmaceuticals' acquisition of Azora Therapeutics brings a colon-targeted aryl hydrocarbon receptor agonist into a pipeline now backed by up to $64 million in private placement financing, with IND-enabling studies and a Phase 1 initiation in ulcerative colitis targeted for mid-2027. For CMO/CDMO partners and formulation teams, the timeline sets a near-term window for process development engagement on a novel oral candidate engineered for minimal systemic exposure.

Azora's lead asset, AT177, is a fully synthetic, patented AhR agonist rationally designed to concentrate pharmacologic activity at the colonic mucosa while limiting systemic absorption. The mechanism addresses a documented liability in the AhR class: systemic activation has been associated with immunosuppression and potential long-term safety risks. Localized delivery is therefore both a clinical differentiator and a formulation challenge that will require careful characterization during IND-enabling work.

The private placement is structured in two tranches. An initial closing of approximately $32 million in gross proceeds, including conversion of notes assumed in the acquisition, was exchanged for pre-funded warrants covering 11,780,948 shares at $2.7489 per warrant. A second tranche of up to $32 million becomes available upon Phase 1 clinical study initiation, triggering additional pre-funded and common warrants at the same combined purchase price. Coastlands Capital led the round, with participation from Boxer Capital Management, Stonepine Capital Management, and AuGC BioFund, alongside institutional investors and company insiders.

Proceeds are earmarked primarily for AT177's IND-enabling studies and the subsequent Phase 1a and Phase 1b studies in ulcerative colitis. Matt Davidson, PhD, co-founder of Azora and incoming chief development officer at Adial, noted that AT177's design begins from fundamental UC biology, positioning the compound to address both efficacy and the systemic safety profile that has constrained earlier AhR-targeting approaches. Davidson joins Adial's board as a newly appointed director concurrent with the close.

The combined company's ability to reach the Phase 1 initiation milestone will determine whether the second $32 million tranche is drawn, making execution of IND-enabling studies the immediate operational priority and the clearest near-term checkpoint for external partners tracking the program.

Source: Adial Pharmaceuticals Inc. via GlobeNewswire, June 11, 2026. Conference call hosted June 11, 2026 at 1:00 PM ET.